PROTECHT Score (Cancer-Associated VTE Risk)
PROTECHT score (Verso 2012): cancer site plus thrombocytosis, anemia/ESA use, leukocytosis, high BMI, and platinum or gemcitabine chemotherapy give a score banding cancer-associated VTE risk (≥ 3 high).
Open the calculator → Runs in your browser. Data leaves only if you deliberately send a problem report from the interactive tool.
Example
- Cancer site
- Very high risk: stomach, pancreas (2)
- Platelets ≥ 350 ×10⁹/L
- Yes
- Hemoglobin < 10 g/dL or ESA use
- No
- Leukocytes > 11 ×10⁹/L
- No
- BMI ≥ 35 kg/m²
- No
- Platinum-based chemotherapy
- Yes
- Gemcitabine chemotherapy
- No
Result: PROTECHT score 4 — high VTE risk (>= 3).
The tool opens with these values already filled in. Replace them with your own.
What the result means
- 0-2
- Low-intermediate cancer-associated VTE risk.
- >= 3
- High risk. Khorana base plus platinum and gemcitabine chemotherapy points. Not a thromboprophylaxis order.
What you enter
- Cancer site (0/1/2 points)
- Platelets ≥ 350 ×10⁹/L (+1)
- Hemoglobin < 10 g/dL or ESA use (+1)
- Leukocytes > 11 ×10⁹/L (+1)
- BMI ≥ 35 kg/m² (+1)
- Platinum-based chemotherapy (+1)
- Gemcitabine chemotherapy (+1)
How this is calculated
Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the PROTECHT score. Intern Emerg Med. 2012;7(4):291-292. Read the source ↗
A reference and educational tool. Not medical, legal, or financial advice, and not a substitute for clinician judgment.